Imunon, Inc. (IMNN) Balance Sheet

The consistent decline in total assets and equity over the last ten quarters suggests a business model that is rapidly consuming its remaining resources. This trajectory indicates that the company is nearing a critical juncture where the current capital structure may no longer support ongoing research activities without significant dilution.

The current ratio of 1.59 provides a superficial sense of stability, but the absolute cash level relative to the historical burn rate suggests a high risk of liquidity exhaustion. Investors should monitor the company's ability to secure non-dilutive funding, as the current cash position appears insufficient for long-term operational continuity.

The massive deficit in retained earnings highlights the historical value destruction associated with the company's previous clinical efforts. The current equity base is essentially a residual value that remains highly sensitive to further operational losses and the potential for future equity-based financing rounds.